The effects of Momordica charantia (bitter melon) supplementation in patients with primary knee osteoarthritis: A single-blinded, randomized controlled trial
Randomized trial
Abstract
In a single-blinded randomized controlled trial, bitter melon (Momordica charantia) supplementation reduced markers and symptoms in patients with primary knee osteoarthritis, supporting an anti-inflammatory benefit relevant to arthritis.
Referenced for these plants
How to cite
Soo May, L., Sanip, Z., Ahmed Shokri, A., Abdul Kadir, A. and others (2018) 'The effects of Momordica charantia (bitter melon) supplementation in patients with primary knee osteoarthritis: A single-blinded, randomized controlled trial', Complementary Therapies in Clinical Practice, 32, pp. 181-186. doi:10.1016/j.ctcp.2018.06.012
This reference is part of the evidence base for the Omnia Sana plant database. Source links open the original publication; Omnia Sana does not host third-party content.